Detalles de la búsqueda
1.
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.
BMC Cancer
; 23(1): 708, 2023 Jul 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37507657
2.
Disease progression model using the integrated Alzheimer's Disease Rating Scale.
Alzheimers Dement
; 19(6): 2253-2264, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36450003
3.
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Invest New Drugs
; 38(5): 1570-1579, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32140889
4.
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.
Liver Int
; 39(8): 1468-1477, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30963691
5.
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
Br J Cancer
; 119(10): 1208-1214, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30318515
6.
Disposition and metabolism of [14C]-galunisertib, a TGF-ßRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics.
Xenobiotica
; 48(4): 382-399, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28436712
7.
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
Int J Mol Sci
; 18(5)2017 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28481241
8.
Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer.
Br J Clin Pharmacol
; 82(3): 717-27, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27136318
9.
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-ß receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
Invest New Drugs
; 33(2): 357-70, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25529192
10.
Mechanism for enhanced absorption of a solid dispersion formulation of LY2300559 using the artificial stomach duodenum model.
Mol Pharm
; 12(4): 1131-40, 2015 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-25723790
11.
Defining a therapeutic window for the novel TGF-ß inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model.
Br J Clin Pharmacol
; 77(5): 796-807, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24868575
12.
Handling missing data in a duloxetine population pharmacokinetic/pharmacodynamic model - imputation methods and selection models.
Pharm Res
; 31(10): 2829-43, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24792830
13.
Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease.
Clin Pharmacol Ther
; 113(6): 1258-1267, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36805552
14.
Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease.
Alzheimers Dement (N Y)
; 9(2): e12404, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37388759
15.
Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug-drug interaction studies for CYP2C9.
J Pharmacokinet Pharmacodyn
; 39(2): 147-60, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22270321
16.
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
JAMA Neurol
; 79(10): 1015-1024, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36094645
17.
Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed.
Eur J Pharm Sci
; 161: 105781, 2021 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33667665
18.
Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
Cancer Med
; 10(9): 3059-3067, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33811482
19.
Safety and activity of the TGFß receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
J Immunother Cancer
; 9(3)2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33688022
20.
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
J Clin Oncol
; 39(10): 1108-1118, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33555926